Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II drugs for Bladder Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Istisociclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Istisociclib overview
Istisociclib (KB-0742) is under development for the treatment of castration resistant prostate cancer, soft tissue sarcoma and MYC-dependent acute myeloid leukemia, solid tumors, ovarian cancer, chordoma, non-Hodgkin lymphoma, soft tissue sarcoma, bladder cancer, rectal cancer , germ cell tumors; uterine cancer, colorectal cancer, myxoid liposarcoma, non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), triple-negative breast cancer (TNBC), gastric cancer, gastroesophageal (GE) junction carcinomas, diffuse large B-cell carcinoma, NUT midline carcinoma, adenoid cystic carcinoma, neuroblastoma tumors, ewing sarcoma (EW) and alveolar rhabdomyosarcoma (ARMS). It is administered through oral route as a capsule. The drug candidate acts by targeting cyclin-dependent kinase 9 (CDK9). It is developed based on small molecule microarray (SMM) platform.
Kronos Bio overview
Kronos Bio is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for cancer and other serious diseases. The company pipeline products include KB-0742, an oral cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of MYC-amplified and other transcriptionally addicted solid tumors, and KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. It collaborates with other companies for research and development. The company operates in Massachusetts and California. Kronos Bio is headquartered in San Mateo, California, the US.
For a complete picture of Istisociclib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
